About Vida Ventures
Vida Ventures is a venture capital firm founded in 2017. It is primarily based out of Boston, United States. As of Jun 2026, Vida Ventures is an active investor, having invested in 48 companies, with 5 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Series B round of SonoThera Overall, Vida Ventures portfolio has seen 9 IPOs and 13 acquisitions including key companies like Sutro Biopharma, AskBio and Dyne Therapeutics. A lot of funds co-invest with Vida Ventures, with names like Orbimed sharing a substantial percentage of its portfolio. Vida Ventures has team of 21 people including 6 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 7 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Vida Ventures' List of Top Investments
Vida Ventures has a portfolio of 48 companies. Their most notable investments are in Redbook and Affini-T Therapeutics.Their portfolio spans across United States, India, China and 2 more locations. They have invested in Life Sciences, High Tech, HealthTech and 4 other sectors, across stages such as Series A, Series B and 7 more. Here is the list of top investments by Vida Ventures:Developer of antibody-based therapeutics for cancer therapy. The company uses cell-free protein synthesis platform XpressCF technology led to the discovery of STRO-001 and STRO-002, for B-cell malignancies, ovarian and endometrial cancers.
Key facts about Sutro Biopharma
- Founded Year: 2003
- Location: United States
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $175M
- Employee Count: 211 as on Apr 30, 2026
- Investors: Amgen Business Development, Celgene and 17 Others
- Latest Funding Round: Series E, Jul 26, 2018, $*****
- Highlight: Public
2. AskBio
Developer of AAV technologies for treating genetic and complex disorders. The company is engaged in the development and delivery of novel protein and cellular-based therapies through the design of proprietary recombinant Adeno associated virus (AAV) Biological Nano Particles (BNP). The gene delivery technology platform provides unsurpassed transduction efficiency, "ramp-up" expression capabilities, with tissue targeting and de-targeting properties. Its product pipeline includes drugs to treat muscular dystrophy, hemophilia B, congestive heart failure, epilepsy, retinitis pigmentosa, and osteoporosis.
Key facts about AskBio
- Founded Year: 2001
- Location: Durham (United States)
- Stage: Acquired
- Total Funding till date: $235M
- Employee Count: 527 as on May 31, 2026
- Investors: Columbus Venture Partners, Vida Ventures and 4 Others
- Latest Funding Round: Grant (prize money), Sep 02, 2020, $*****
- Highlight: Acquired
Dyne Therapeutics provides nucleic acid therapies for rare diseases. The company offers proprietary technology for muscles disorder, myotonic dystrophy, and others. The company also offers treatments for rare genetic diseases, drug discovery and development, linker chemistry, antibiotics engineering, and others.
Key facts about Dyne Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Stage: Public
- Total Funding till date: $166M
- Employee Count: 291 as on May 31, 2026
- Investors: Atlas Venture, Franklin Templeton India and 5 Others
- Latest Funding Round: Series B, Aug 10, 2020, $*****
- Highlight: Public
Developer of precision therapeutics for cancer treatment. It offers a lead drug candidate which is a RIPTAC therapeutic that utilizes androgen receptor as a targeting protein to selectively deliver the drug for the treatment of metastatic, castrate-resistant prostate cancer, and tumors.
Key facts about Halda Therapeutics
- Founded Year: 2019
- Location: New Haven (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $217M
- Investors: Access Industries, Boxer Capital and 10 Others
- Latest Funding Round: Series B, Aug 12, 2024, $*****
- Highlight: Acquired
Developer of radiopharmaceuticals for solid tumor cancers. The company had developed platforms to generate tumor-targeting agents for radiotherapy that are designed for high tumor penetration and long residence time. The therapeutic radioisotope molecules developed eliminates tumors from the body and minimize the side effects.
Key facts about Aktis Oncology
- Founded Year: 2021
- Location: Boston (United States)
- Stage: Public
- Total Funding till date: $336M
- Employee Count: 93 as on May 31, 2026
- Investors: Janus Henderson Investors, RTW Investments and 16 Others
- Latest Funding Round: Series B, Sep 20, 2024, $*****
- Highlight: Public
Vida Ventures' Year-on-Year Investment Trends
Vida Ventures has invested in 48 companies over the last 9 years, with an average of 3 new investments annually in the last 5 years. In 2025, it made 4 investments, while as of Jun 2026, it has made 4 investments in this year. Its most recent first time investment was in SonoThera and most recent follow-on round was in Poplar Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 1 | 4 |
2025 | 4 | 0 | 4 |
2024 | 4 | 2 | 6 |
2023 | 1 | 4 | 5 |
2022 | 1 | 5 | 6 |
2021 | 9 | 2 | 11 |
2020 | 10 | 4 | 14 |
2019 | 8 | 1 | 9 |
2018 | 3 | 0 | 3 |
2017 | 4 | 0 | 4 |
Vida Ventures' Investments by Stage
Vida Ventures has made 16 investments in Series A stage with an average round size of $120M, 10 investments in Series B stage with an average round size of $100M and 7 investments in Seed stage with an average round size of $16.2M.Stage of entry | No. of Investments |
|---|---|
Series A | 16 |
Series B | 10 |
Seed | 7 |
Series C | 6 |
PE | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
Vida Ventures' Investments by Sector
Vida Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, HealthTech, Consumer and Enterprise Applications. Notably, it has invested in 44 Tech companies, 43 Enterprise (B2B) companies, 4 Consumer (B2C) companies and at least 3 companies focusing on Software.Sector | No. of Investments |
|---|---|
Life Sciences | 42 |
High Tech | 6 |
HealthTech | 2 |
Consumer | 1 |
Enterprise Applications | 1 |
Others | 3 |
Note: We have considered here, only first round of investments
Vida Ventures' Investments by Geography
Vida Ventures has made most investments in United States (41), followed by India where it has made 3 investments.Country | No. of Investments |
|---|---|
United States | 41 |
India | 3 |
China | 1 |
Denmark | 1 |
France | 1 |
Note: We have considered here, only first round of investments
Vida Ventures' recent investments
Vida Ventures has made 4 investments in 2026 so far. SonoThera and Adcendo are the latest among them.Here are the most recent investments by Vida Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 08, 2026 | United States | Series B | 4468 | ||
Apr 14, 2026 | Denmark | Series C | 7797 | [+15] | |
Mar 03, 2026 | United States | Series A | 8785 | ||
Jan 08, 2026 | United States | Series A | 7942 | [+1] | |
Dec 01, 2025 | United States | Series B | 8671 |
IPOs and Publicly Listed companies in Vida Ventures' Portfolio
9 of Vida Ventures' portfolio companies have become public. Avalyn Pharma got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Apr 2026 at marketcap of $753M and Aktis Oncology got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $945M.Here are Vida Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Apr 30, 2026 | Sep 27, 2023 | Series C | 4539 | |
Jan 09, 2026 | Mar 18, 2021 | Series A | 3930 | |
Feb 08, 2024 | Jan 13, 2020 | Series A | 5871 | |
Nov 01, 2021 | Oct 29, 2020 | Unattributed | 6247 | |
Oct 16, 2020 | May 04, 2020 | Series C | 5686 |
Acquired companies in Vida Ventures' Portfolio
13 companies from Vida Ventures' portfolio have been acquired. The most recent acquisition was Candid Therapeutics in May 2026 by UCB for $*****.Here are Vida Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 03, 2026 | Sep 09, 2024 | Series D | 2594 | |
Mar 31, 2026 | Feb 16, 2021 | Series A | 5486 | |
Nov 17, 2025 | Aug 12, 2024 | Series B | 2583 | |
Jul 01, 2025 | Nov 24, 2021 | Seed | 8570 | |
May 21, 2025 | Aug 18, 2021 | Series B | 7461 |
Team profile of Vida Ventures
Vida Ventures has a team of 21 members including 6 Partners and 3 Principals located in United States. Vida Ventures' team does not sit on the board of any company as of now.Here is a list of top team members in Vida Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Los Angeles | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - | |
Partner | Boston | - | - | |
Partner | Santa Monica | - | - | |
Partner | San Francisco | - | - | |
Principal | Boston | - | - | |
Principal | Boston | - | - | |
Principal | Los Angeles | - | - |
Co-investors of Vida Ventures
Over the past 9 years, 454 investors have co-invested in Vida Ventures's portfolio companies. This includes funds and angels.
- Invested before Vida Ventures: HHS, Arch Venture Partners and 96 others have invested in rounds before Vida Ventures. There are 4 companies where HHS has invested before Vida Ventures and 4 companies where Arch Venture Partners has invested before Vida Ventures.
- Top Co-investors of Vida Ventures: 229 investors entered a company along with Vida Ventures. These include investors like Orbimed (8 companies).
- Invested after Vida Ventures: A total of 127 investors have invested in Vida Ventures's portfolio after their investments. Top Investors include Janus Henderson Investors (5 companies), Citadel (5 companies) and RA Capital Management (4 companies).
Recent News related to Vida Ventures
•
SonoThera raises $125M for non-viral gene therapy approachEndpoints•Jun 10, 2026•SonoThera, Medical Excellence Capital, UCB Ventures, Leaps by Bayer and 10 others
•
•
Adcendo ApS Completes $75 Million Series C FinancingCNW•Apr 14, 2026•Jeito, Bpifrance, Danmarks Eksport og Investeringsfond, Adcendo and 12 others
•
•
Poplar Therapeutics Secures $50M Series A for Anti-IgE Therapy DevelopmentPulse 2.0•Jan 09, 2026•Vida Ventures, SR One, ALDEN POPLAR CREEK REHAB AND HEALTH CARE CENTER, INC., Poplar Therapeutics and 2 others
•
•
Protego gets $130M for AL amyloidosis drug from leaders behind VyndaqelEndpoints•Dec 01, 2025•Protegobio, Brown Rudnick, Omega Funds, Novartis Venture Fund and 8 others
•
•
The Endpoints 11: Third Arc raises $198.5M to tackle major disease targetsEndpoints•Sep 19, 2025•Third Arc Bio, Vida Ventures
•
